Abstract:Highlights • Intrathecal injection of 10 nmol NPFF potentiated morphine-induced analgesia. • Intrathecal injection of 10 pmol NPFF attenuated morphine-induced analgesia. • Both the pro- and anti-opioid effects of NPFF were mediated by NPFFR2. • Blockade of spinal NPFFR2 selectively regulated MOR agonists-induced analgesia. • NPFF exhibited anti-morphine effects in primary-cultured spinal neurons. Increasing evidence indicates that neuropeptide FF (NPFF) produces analgesic effects and augments opioid-induced analgesia at the spinal level. However, our recent research demonstrated that NPFF exerted complex opioid-modulating effects in an inflammatory pain model after intrathecal (i.t.) injection. Consistent with previous findings, we found that i.t. NPFF dose-dependently attenuated complete Freund's adjuvant-induced pain hypersensitivity. Interestingly, pharmacological results illustrated that NPFF exhibited opposite opioid-modulating effects at the spinal level depending on its administration dosage, wherein i.t. NPFF potentiated morphine-induced anti-allodynia at the dose of 10 nmol, while attenuated morphine analgesia at an ultra-low-dose of 10 pmol. Behavioral results obtained from neuropeptide FF receptor 2 (NPFFR2) knockout animals suggested that both pro- and anti-opioid effects of NPFF were mediated by NPFFR2. Moreover, these modulating effects of spinal NPFFR2 were selectively targeting mu-opioid receptor, had no effect on delta- and kappa-opioid receptor agonist-induced analgesia. Finally, the opioid-modulating effects of NPFF were further verified using in vitro calcium imaging assay, demonstrating that pretreated with NPFF in primary-cultured spinal neurons significantly attenuated the inhibitory effects of morphine on high-K + -induced neuronal excitability. Taken together, our results suggested that NPFF exhibited dual modulating effects on morphine-induced analgesia after i.t. administration, which provides a possible mechanism to explain the complex opioid-modulating effects of endogenous NPFF systems. Graphical abstract Download: Download high-res image (107KB) Download: Download full-size image

VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Effects of Neuropeptide FF and Related Peptides on the Antinociceptive Activities of VD-hemopressin(α) in Naive and Cannabinoid-Tolerant Mice.

Antinociceptive Effects of Central Administration of the Endogenous Cannabinoid Receptor Type 1 Agonist VDPVNFKLLSH-OH [(M)vd-Hemopressin(α)], an N-terminally Extended Hemopressin Peptide.

Effects of Neuropeptide Ff System on Cb1 and Cb2 Receptors Mediated Antinociception in Mice

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

MP-13, a novel chimeric peptide of morphiceptin and pepcan-9, produces potent antinociception with limited side effects

Pharmacological Characterization of Rat VD-hemopressin(α), an Α-Hemoglobin-derived Peptide Exhibiting Cannabinoid Agonist-Like Effects in Mice

Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.

Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice.

CB1 Cannabinoid Receptor Agonist Mouse VD-hemopressin(α) Produced Supraspinal Analgesic Activity in the Preclinical Models of Pain.

Pharmacological Characterization of EN-9, a Novel Chimeric Peptide of Endomorphin-2 and Neuropeptide FF That Produces Potent Antinociceptive Activity and Limited Tolerance

NaV1.7 Channel Blocker [Ala5, Phe6, Leu26, Arg28]GpTx-1 Attenuates CFA-induced Inflammatory Hypersensitivity in Rats via Endogenous Enkephalin Mechanism

Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception.

Effects of Nociceptin (13–17) in Pain Modulation at Supraspinal Level in Mice

OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration

The dual modulating effects of neuropeptide FF on morphine-induced analgesia at the spinal level

Peripheral and Central Sites of Action for Anti-Allodynic Activity Induced by the Bifunctional Opioid/npff Receptors Agonist BN-9 in Inflammatory Pain Model

Analgesic Tolerance and Cross-Tolerance to the Cannabinoid Receptors Ligands Hemopressin, VD-hemopressin(α) and WIN55,212-2 at the Supraspinal Level in Mice